Welcome to University of Mumbai, Department of Biophysics


Bioinformatics Database on
"Radiosensitisers and Radioprotectors"

Alphabetical Search   >  P   >  Probucol                                                                                                                                                                 Top

Probucol

Go To:


General Features                  Clinical Study                  Chemical Intervention                 Pharmacological Aspects                 
Radiobiological Aspects                  Biological Models                  Biological Target                  Toxicity                 


GENERAL FEATURES

Name: Probucol
Trade name: Powdered probucol(Lorelco)[1]
Chemical name: 4,4'-isopropylidenedithio-bis-(2,6-di-tert-butylphenol)[2]
Molecular Weight: 516.84 g/mol[2]
Source: Probucol is a synthetic drug synthesized at Dow Chemical[3]
Structure: [2],[4],[5]
Chemical Nature: Melting Point 125-128oC [2]
lipophilic phenolic compound[2]
very soluble in acetone, chloroform and dimethylformate, soluble in ethanol, ether and carbon tetrachloride, insoluble in water[2]
Actions
& Indications:
Pharmcological Action-
anti-atherogenetic in rats[6]
antioxidant[7]
Therapeutic indications:
probucol is used for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL-C levels[8]
Preclinical study-
Notes:
REFERENCES
1. Bonsack ME et al, Radioprotection of the intestinal mucosa of rats by Probucol. Radiation Research. 1999;151(1):69-73.
http://dx.doi.org/10.2307/3579749
2. 6 : Antioxidants Properties of Probucol by Niki E, Noguchi N ; In : Part III : Phenolic Antioxidants; In : Handbook of Synthetic Antioxidants, edited by Packer L, Cadenas E, CRC Press, 1997, Page no. 226-227.
https://books.google.com/books?id=tE52C5Hs0xwC&pg=PA226&lpg=PA226
3. 8 : Probucol by Steinberg D, Witztum JL ; In : Drug Treatment of Hyperlipidemia, edited by Rifkind BM, CRC Press, 1991, page no. 175.
https://books.google.com/books?id=GOtS1BKaG3gC&pg=PA175
4. Araki T, Kitaoka H, Antioxidative properties of Probucol estimated by the reactivity with superoxide and by electrochemical oxidation. Chem. Pharm. Bull. 2001;49(8) :943—947.
http://doi.org/10.1248/cpb.49.943
5. Buckley MM et al, Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989 ;37(6):761-800.
http://dx.doi.org/10.2165/00003495-198937060-00002
6. Eisenberg S, The effects of probucol on the levels, structure, composition and metabolism of plasma lipoprotein in rats. Biochim Biophys Acta. 1993;1167(1):79-84.
http://dx.doi.org/10.1016/0005-2760(93)90220-4
7. Bonnefont-Rousselot D et al, Antioxidant effect of Probucol on RO2·/O2·-induced peroxidation of human low-density lipoproteins. Radiat. Res. 1999;151(3):343-353.
http://dx.doi.org/10.2307/3579947
8. Baldassarre D et al, Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. J Cardiovasc Pharmacol. 1997;30(6):7849
http://www.ncbi.nlm.nih.gov/pubmed/9436818